Answers are grounded in this paper and cite their sources.
Comprehensive Summary The trifluoromethyl (CF 3 ) group is an important motif in drug discovery, and its radiolabeled variants with fluorine‐18 and carbon‐11 have become increasingly valuable for positron emission tomography (PET). This review provides a comprehensive overview of the strategies developed to date for the construction of [ 18 F/ 11 C]CF 3 groups, including both 18 F‐fluorination and 18 F/ 11 C‐trifluoromethylation. The 18 F‐fluorination strategy, which relies on the direct utility of readily available [ 18 F]fluoride, offers a single‐step route to [ 18 F]CF 3 ‐containing compounds through halogen exchange or the radiofluorination of gem ‐difluoroalkenes. However, the substrate scope and molar activity often remain challenging due to 19 F‐dilution. The 18 F/ 11 C‐trifluoromethylation approach leverages well‐established trifluoromethylation chemistry to transfer a preformed [ 18 F]CF 3 or [ 11 C]CF 3 unit to the target substrate, enabling the late‐stage preparation of structurally diverse molecules, including complex drug‐like compounds, peptides, and biomolecules. Recent breakthroughs in aliphatic radiotrifluoromethylation have substantially expanded the radiochemical space, addressing a long‐standing issue in the field. Despite these impressive advances, challenges such as molar activity, reagent accessibility, and practical utility in routine tracer production need to be addressed. This review highlights the key developments, current challenges, and future directions of [ 18 F/ 11 C]trifluoromethyl groups in radiochemistry.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: